Meeting
2021 ASCO Annual Meeting
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
Authors
Frederik Marmé
Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Mannheim, Germany
Frederik Marmé , Elmar Stickeler , Jenny Furlanetto , Carsten Denkert , Marcus Schmidt , Mattea Reinisch , Toralf Reimer , Wolfgang Janni , Michael Untch , Bruno Valentin Sinn , Volker Moebus , Laura Michel , Laura Schoellhorn , Sabine Schmatloch , Julia Rey , Sibylle Loibl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04595565
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS602)
DOI
10.1200/JCO.2021.39.15_suppl.TPS602
Abstract #
TPS602
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
First Author: Lisa A. Carey
First Author: Sara M. Tolaney
Poster
2023 ASCO Annual Meeting
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.
First Author: Olga Kantor
Poster
2023 ASCO Annual Meeting
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
First Author: Jai Min Ryu